Impact on the quality of life of the treatment of adductor spasmodic dysphonia with botulinum toxin A

Impacto en la calidad de vida del tratamiento de disfonía espasmódica aductora con toxina botulínica A


Introduction. Laryngeal dystonia or spasmodic dysphonia is characterized by involuntary contractions of internal laryngeal muscles that are triggered when speaking, being the adductor form the most frequent. Botulinum toxin injection is the management of choice. There are several validated instruments to assess response to therapy, one of them is the Voice Handicap Index-10 (VHI-10) questionnaire. The objective of this study is to characterize patients with adductor spasmodic dysphonia and evaluate the impact of the toxin on their quality of life.

Method. A descriptive retrospective study was carried out in adult patients with a diagnosis of adductor spasmodic dysphonia treated with botulinum toxin A, between 2013-2021 at the Hospital Clínico Universidad de Chile. The epidemiological data of the patients and the VHI-10 survey were obtained before and after one month of each toxin injection was requested.

Results. 55 patients (218 procedures) were included. The average dose used was 9.18 IU with an average interval of 7.4 months. The average VHI-10 score in the initial evaluation was 29.4 and post-infiltration was 14.96, being this difference significant (p <0.000001). In our series, almost a third had an associated neurological pathology, and 3.67% of mild and transitory complications were reported.

Conclusion. Adductor spasmodic dysphonia has a great impact on the quality of life of patients, which is significantly reduced by injecting botulinum toxin A, a procedure that has been shown to be safe and effective.


Download data is not yet available.

Citado por


Carolina Oliva Guerrero
Luis Barahona Acevedo
Javiera Castro Arenas
Christian Olavarría Leiva


Whurr R, Lorch M. Review of differential diagnosis and management of spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg. 2016;24(3):203-207. Doi:

Lorch MP, Whurr R. Tracing Spasmodic Dysphonia: The Source of Ludwig Traubes Priority. Ann Otol Rhinol Laryngol. 2016;125(8):672-676. Doi:

Mor N, Simonyan K, Blitzer A. Central voice production and pathophysiology of spasmodic dysphonia. Laryngoscope. 2018;128(1):177-183. Doi:

Simonyan K, Ludlow CL. Abnormal structure-function relationship in spasmodic dysphonia. Cereb Cortex. 2012;22(2):417-425. Doi:

Chen M, Summers RLS, Prudente CN, et al. Transcranial magnetic stimulation and functional magnet resonance imaging evaluation of adductor spasmodic dysphonia during phonation. Brain Stimul. 2020;13(3):908-915. Doi:

Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG. Spasmodic Dysphonia: A Review. Part 1: Pathogenic Factors. Otolaryngol - Head Neck Surg (United States). 2017;157(4):551-557. Doi:

Ludlow CL, Domangue R, Sharma D, et al. Consensus-based attributes for identifying patients with spasmodic dysphonia and other voice disorders. JAMA Otolaryngol - Head Neck Surg. 2018;144(8):657-665. Doi:

Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG. Spasmodic Dysphonia: A Review. Part 2: Characterization of Pathophysiology. Otolaryngol - Head Neck Surg (United States). 2017;157(4):558-564. Doi:

Brunetto B, Nazar R, Olavarría C, Gutiérrez A, del Peso G, Miranda M, Painepán JC. Experiencia con toxina botulínica en el tratamiento de la disfonía espasmódica. Rev. Otorrinolaringol. Cir. Cabeza y cuello. 2014, vol. 64, p. 105-112. Url:

Faham M, Ahmadi A, Silverman E, Harouni GG, Dabirmoghaddam P. Quality of life after botulinum toxin injection in patients with adductor spasmodic dysphonia; a systematic review and meta-analysis. Journal of Voice. 2021 Mar 1;35(2):271-83. Doi:

Faham M, Torabinezhad F, Murry T, et al. Quality of life and voice changes after a single injection in patients with ADSD over time. J Voice 2019 Sep;33(5):721-727. Doi:

Rosen C, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the Voice Handicap Index-10. Laryngoscope. 2004;114:1549–1556. Doi:

Núñez-Batalla F, Corte-Santos P, Señaris-González B, Llorente-Pendás JL, Gorriz-Gil C, Suarez-Nieto C. Adaptación y validación del índice de incapacidad vocal (VHI-30) y su versión abreviada (VHI-10) al español. Acta Otorrinolaringológica Española. 2007 Nov 1;58(9):386-92. Doi:

Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. European Journal of Neurology. 2010 Jul;17:28-30. Doi:

Patel AB, Bansberg SF, Adler CH, Lott DG, Crujido L. The Mayo Clinic Arizona spasmodic dysphonia experience: a demographic analysis of 718 patients. Annals of Otology, Rhinology & Laryngology. 2015 Nov;124(11):859-63. Doi:

Paddle P, Husain I, Moniz C, Turner S, Franco Jr RA. Long-term dose stability of onabotulinumtoxinA injection for adductor spasmodic dysphonia: a 19-year single institution experience. Frontiers in surgery. 2017 Nov 29;4:70. Doi: eCollection 2017

French G, Bosch JD, Randall DR. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort. Journal of Otolaryngology-Head & Neck Surgery. 2020 Dec;49(1):1-4. Doi:

Blitzer A, Brin MF, Simonyan K, Ozelius LJ, Frucht SJ. Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30‐year experience. The Laryngoscope. 2018 Jan;128:S1-9. Doi:

Ozgursoy SK, Vargas ER, Heckman MG, Rutt AL. Demographics and coexisting tremor, cervical dystonia and vocal fold disorders in a group of patients with spasmodic dysphonia. Acta Otorhinolaryngologica Italica. 2020 Jun;40(3):198. doi:

Marchese MR, D'Alatri L, Bentivoglio AR, Paludetti G. OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): functional results and the role of dosage. Toxicon. 2018 Dec 1;155:38-42. Doi:

Shoffel‐Havakuk H, Rosow DE, Lava CX, Hapner ER, Johns III MM. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: a national survey. The Laryngoscope. 2019 Jul;129(7):1650-6. Doi:

Young DL, Halstead LA. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues. Journal of Voice. 2014 Sep 1;28(5):614-7.) doi:

Bradley JP, Barrow EM, Hapner ER, Klein AM, Johns III MM. Botulinum toxin-a dosing trends for adductor spasmodic dysphonia at a single institution over 10 years. Journal of Voice. 2017 May 1;31(3):363-5. Doi:

McGarey Jr PO, Simpson CB, Daniero JJ. Practice Patterns and Barriers in Botulinum Toxin Injection for the Treatment of Voice Disorders. Journal of Voice. 2020 May 26;S0892-1997(20)30155-7. Doi:

Gilbert MR, Young VN, Smith LJ, Rosen CA. Multidose botulinum toxin A for intralaryngeal injection: a cost analysis. Journal of Voice. 2019 Mar 1;33(2):159-61. Doi:

Jacobson BH, Johnson A, Grywalski C, et al. The voice handicap index (VHI): development and validation. Am J Speech-Lang Pathol. 1997;6:66–70. Doi:

Morzaria S, Damrose EJ. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia. Journal of Voice. 2012 May 1;26(3):378-80. Doi:

Neumann KJ, Dejonckere PH. Voice related quality of life in spasmodic dysphonia: a detailed VHI-analysis before and after botulinum treatment. InMAVEBA 2009 Dec 14 (p. 65). Url:

Novakovic D, Waters HH, D'Elia JB, Blitzer A. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. The Laryngoscope. 2011 Mar;121(3):606-12. Doi:

Yiu Y, Baylor CR, Bamer AM, Shelly S, Klein AM, Garrett CG, Pitman MJ. Validation of the Communicative Participation Item Bank as an Outcome Measure for Spasmodic Dysphonia. The Laryngoscope. 2021 Apr;131(4):859-64. Doi:

Aguayo AM, Corrales MT, Castro GF. Índice de discapacidad vocal pre-y postaplicación de toxina botulínica en pacientes con disfonía espasmódica. Anales Médicos de la Asociación Médica del Centro Médico ABC. 2017 Jun 15;62(2):100-5. Url:

Dharia I, Bielamowicz S. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort. The Laryngoscope. 2020 Nov;130(11):2659-62. Doi:


Download data is not yet available.